Research based on clinical data
The research implemented by the SIRIC team within each of these integrated research programmes is underpinned by clinico-biological cohorts, imaging, epidemiological, public health and quality-of-life databases.
Cohorts and Biocollections
Study of clonal evolution mechanisms and treatment resistance in multiple myeloma.
Coordinator : Cyrille Touzeau, CHUN.
Clinical research protocol : Non-interventional research involving the human person, NCT03807128
MYRACLE is a prospective cohort of patients with multiple myeloma backed by a biocollection dedicated to the identification of mechanisms of resistance to different treatment . The data collected by the MYRACLE study includes socio-demographical, clinical, biological, imaging, treatment and quality of life data collected over time at the different stages of care (diagnosis, relapse/progression, follow-up). In the long-term, this integrative cohort of 600 patients will allow us to determine, thanks to the bioinformatic processing of the biomarkers that influence the treatment response, to evaluate the impact of each treatment on clonal evolution and the principal factors of resistance, such as apoptosis and the P53 network.
In silico prediction of overall survival in a pilot study of a prospective cohort of patients with metastatic breast cancer.
Coordinator : Mario Campone, ICO.
Clinical research protocol : Interventional research involving the human person, NCT03958136
The objective of the EPICURE research protocol is to prove the feasibility of the creation of a clinico-biological database containing dynamic data on the evolution of disease in patients with metastatic or locally advanced breast cancer. The therapeutic care is left up to the doctor and is according to current recommendations for the pathology. This database contains a comprehensive view of the disease and the environment of 300 patients. In the long-term, efficient tools for computer processing and statistical use of this data should allow us to determine the profiles of patients and cancers, and from that, develop innovative personalised therapeutic strategies , and this corresponds perfectly with the SIRIC strategy of moving forward from the current care of cancer towards a more « global » approach.
EX vivo THeranostic Response
Coordinator : Mario Campone, ICO.
Clinical research protocol : Non-interventional research involving the human person
Therex is a biological collection that aims at studying the biological response to different therapeutic agents in samples of breast tissue from patients with non-metastatic breast cancer, before any cancer treatment. It also aims to identify predictive markers of therapy which is efficient in breast cancer treatment.
Evaluation of the prognostic value of PET- FDG imaging in patients with multiple myeloma treated under the Cassiopeia protocol.
Coordinator : Françoise Kraeber-Bodéré, Ancillary study : Cassiopeia, NCT02541383.
A study carried out in collaboration with the IRON LabEX, which makes an imaging platform available for the collection, inter-centre exchange and archiving of imaging data that comes from preclinical research centres and clinical imaging services.
IMAJEM (IMAgerie JEune Myélome – young myeloma imaging)
Imaging data correlated with clinical data.
This database was initiated as a prospective socio-economical study of radiology, backed by clinical research protocol IFM/DFCI 2009. The objective of this project was to identify the best imaging techniquE (MRI or PET-FDG) for evaluating multiple myeloma bone lesions:
Moreau P. et al., Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. J Clin Oncol. 2017 Sep 1;35(25):2911-2918.
Today, this database contains imaging correlated with biological and clinical data and is a source of unique data for setting up « machine learning » so as to carry out diagnosis and follow-up of the evolution of the disease during therapy, in a very fine and standardised manner.
Bailly, C. et al., Interim PET analysis in first line therapy of multiple myeloma: Prognostic value of ΔSUVmax in the FDG-avid patients of the IMAJEM study. Clin Cancer Res. 2018, 24:5219-5224.
Public health databases
Study of occupational and social determinants of health.
Launched in 2009, the Constances cohort is the largest French epidemiological and public health survey carried out by the Inserm and the health insurance funds (Cnam and CPAM). This epidemiological cohort intends to follow 200,000 adult volunteers aged between 19 and 69 under four large themes: occupational risks, aging, social inequalities in health and health problems specific to women. This national database is open to the community of researchers and is used in public health projects, research, and epidemiological monitoring.
In the framework of programme 3 directed by Yves Roquelaure, the epidemiological data from Constances has been used to better understand the dynamics of a return to work and long-term retention of employment after breast cancer. The Ester team is associated with the INSERM UMS 11 (M.Zins, M.Goldberg) for encoding the socio-professional trajectories of the cohort.
Longitudinal Study on Behavioural, Economics and Sociological Changes after Cancer.
Coordinator : Angélique Bonnaud-Antignac.
The objective of compiling and analysing the ELCCA database from the surveys conducted in health establishments, is to identify the socio-economical, psychological and clinical factors that determine the evolution of the quality of life of patients after cancer, in both the short and the long-term.
The Loire-Atlantique Vendee Cancer Registry
An exhaustive and permanent census, since1998, of cancers diagnosed in people residing in the Loire Atlantique or Vendee, for the purpose of monitoring health and for research.
Director : Florence Molinié.
The primary objective of the registry is to contribute to health monitoring and planning through the recurring production of indicators at a local level (made available on the website http://www.santepaysdelaloire.com/registre-des-cancers/). The registry’s data is used in national, regional, and departmental estimations of the incidence and the survival of people with cancer in France.
The research topic of the registry is directed towards evaluating practices for diagnosis/screening and to supporting the general population without selection bias. The registry has specifically developed this type of study in breast cancer, for which the routine collection of information is more abundant and detailed than for other cancers. The study of geographical and social disparity makes up another preferential axis of research. The registry’s data is also used for studies initiated by other local or national organisations.